Short-term use of dapagliflozin shows potential clinical benefits in dogs with heart disease, suggesting non-natriuretic actions.
Short-term PO dapagliflozin was well-tolerated and associated with glucosuria but not natriuresis. Clinical benefit of SGLT2i in dogs with heart disease might include non-natriuretic mechanisms, such as anti-inflammatory, antioxidative, or metabolic effects.
No takes yet. Share an insight, caveat, or question.
Massey et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: